52372-97-1

Usage

General Description

5-Methoxy-1,2,3,4-tetrahydronaphthalen-1-amine, also known as 5-MeO-NaPT, is a chemical compound belonging to the class of substituted amphetamines. It is a hallucinogenic and psychoactive substance that acts as a serotonin receptor agonist. 5-MeO-NaPT is known to produce psychedelic effects similar to those of other hallucinogens, such as visual and auditory distortions, altered perception of time and space, and changes in mood and consciousness. It is considered a designer drug and has been subject to legal restrictions in several countries due to its potential for abuse and harmful health effects. The compound is often consumed for recreational purposes, but its use is associated with significant risks and potential adverse reactions, making it a substance of concern in the context of public health and safety.

InChI:InChI=1/C11H15NO/c1-13-11-7-3-4-8-9(11)5-2-6-10(8)12/h3-4,7,10H,2,5-6,12H2,1H3

Upstream product

• 33892-75-0 5-Methoxy-1-tetralone 
• 52372-99-3 N-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)benzylamine 
• 30069-58-0 5-methoxy-3,4-dihydro-2H-naphthalen-1-one oxime 
• 872539-36-1 (Z)-5-methoxy-3,4-dihydronaphthalen-1(2H)-one oxime 

Downstream Products

• 1426537-95-2 benzyl N-(5-methoxy-1,2,3,4-tetrahydronaphthalene-1-yl)sulfamoylcarbamate 
• 103882-27-5 (R)-(-)-5-methoxy-1,2,3,4-tetrahydro-1-naphthalenamine 

Relevant academic research and scientific papers

MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF

The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.

ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT

The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

Preparation of optical homochiral amine

The invention discloses a preparation method of an optical homochiral amine R-5-methoxy-1-naphthalenamine. The method concretely comprises the following steps: carrying out reducing ammonification on a raw material 5-methoxy-1-tetralone to obtain rac-5-methoxy-1-tetralone, and carrying out enzyme-catalyzed dynamic kinetic resolution on the above racemic amine to obtain R-5-methoxy-1-naphthalenamine. The method has the characteristics of simplicity in operation, easily available raw materials, and realization of good yield and high optical purity of the above product.

Preparation method of chiral compound

The invention discloses a preparation method of a chiral compound S-5-methoxy-1-tetrahydronaphthalene amine. A particular method of the preparation method of the chiral compound S-5-methoxy-1-tetrahydronaphthalene amine comprises the following steps of using 5-methoxy-1-tetralone as a raw material, making the 5-methoxy-1-tetralone react with hydroxylamine to generate oxime, then carrying out catalytic hydrogenation reduction on the oxime through a catalyst to obtain 5-methoxy-1-tetrahydronaphthalene amine, and then carrying out a dynamic kinetic resolution reaction catalyzed by a biological enzyme on the amine, so that the S-5-methoxy-1-tetrahydronaphthalene amine can be obtained. The preparation method of the chiral compound S-5-methoxy-1-tetrahydronaphthalene amine has the characteristics that the operation is simple, a product is high in yield, a resolved product is high in optical purity, and the like, and has extremely high guide value and application value in the preparation process of the S-5-methoxy-1-tetrahydronaphthalene amine.

PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE

The present invention provides compounds of Formula (I), as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

Analogues of σ receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4- tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with added polar functionality and reduced lipophilicity for potential use as positron emission tomography radiotracers

1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl] piperazine 1 (PB28) represents an excellent lead candidate for therapeutic and/or diagnostic applications in oncology. However, because its utility is limited by its relatively high de

10A-AZALIDE COMPOUND HAVING 4-MEMBERED RING STRUCTURE

A 10a-azalide compound having a 4-membered ring structure crosslinked at the 10a- and 12-positions, which is represented by the formula (I), and is effective on even Haemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).

SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS

Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.

Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof

The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers,—savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.

Substituted aryl 1,4-pyrazine derivatives

Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.